X4 Pharmaceuticals (NASDAQ:XFOR) Sets New 1-Year Low - Here's What Happened

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report)'s share price hit a new 52-week low on Monday . The company traded as low as $0.17 and last traded at $5.74, with a volume of 1823227 shares changing hands. The stock had previously closed at $0.19.

Analyst Upgrades and Downgrades

Several analysts have weighed in on XFOR shares. HC Wainwright boosted their price objective on X4 Pharmaceuticals from $1.50 to $7.00 and gave the stock a "buy" rating in a report on Friday. Cantor Fitzgerald reissued an "overweight" rating and set a $90.00 price target on shares of X4 Pharmaceuticals in a research note on Wednesday, March 26th.

X4 Pharmaceuticals Stock Performance

The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The stock has a market cap of $646.02 million, a price-to-earnings ratio of -41.33 and a beta of 0.58. The stock's fifty day moving average is $7.67 and its 200-day moving average is $13.19.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($4.13) by $4.17. The firm had revenue of $28.81 million during the quarter, compared to the consensus estimate of $7.03 million. On average, analysts forecast that X4 Pharmaceuticals, Inc. will post -0.68 EPS for the current year.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its stake in shares of X4 Pharmaceuticals by 4.0% during the 4th quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company's stock worth $477,000 after purchasing an additional 24,948 shares during the last quarter. Deutsche Bank AG increased its position in X4 Pharmaceuticals by 559.6% during the fourth quarter. Deutsche Bank AG now owns 267,628 shares of the company's stock worth $195,000 after buying an additional 227,051 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $30,000. Bank of America Corp DE increased its holdings in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company's stock worth $98,000 after acquiring an additional 22,485 shares during the last quarter. Finally, Acorn Capital Advisors LLC acquired a new position in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $5,363,000. 72.03% of the stock is owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.